All In Biotech

Drug Trial Radar · NCT00405964

Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)

Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER)

Last checked: Nov 20, 2026Latest source record: May 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 716 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

716

Actual

Start

Sep 2006

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Dec 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis (PER)

Conditions

  • Allergic Rhinitis

Interventions

  • 5-mg DesloratadineDrug

    5-mg Desloratadine tablet, once daily for 12 weeks

  • Placebo tabletDrug

    Placebo tablet, once daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of TreatmentTime frame: Baseline and Days 1-29

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.